Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination

CONTEXT Current recommendations for women who have a BRCA1 or BRCA2 mutation are to undergo breast surveillance from age 25 years onward with mammography annually and clinical breast examination (CBE) every 6 months; however, many tumors are detected at a relatively advanced stage. Magnetic resonance imaging (MRI) and ultrasound may improve the ability to detect breast cancer at an early stage. OBJECTIVE To compare the sensitivity and specificity of 4 methods of breast cancer surveillance (mammography, ultrasound, MRI, and CBE) in women with hereditary susceptibility to breast cancer due to a BRCA1 or BRCA2 mutation. DESIGN, SETTING, AND PARTICIPANTS A surveillance study of 236 Canadian women aged 25 to 65 years with BRCA1 or BRCA2 mutations who underwent 1 to 3 annual screening examinations, consisting of MRI, mammography, and ultrasound at a single tertiary care teaching hospital between November 3, 1997, and March 31, 2003. On the day of imaging and at 6-month intervals, CBE was performed. MAIN OUTCOME MEASURES Sensitivity and specificity of each of the 4 surveillance modalities, and sensitivity of all 4 screening modalities vs mammography and CBE. RESULTS Each imaging modality was read independently by a radiologist and scored on a 5-point Breast Imaging Reporting and Data System scale. All lesions with a score of 4 or 5 (suspicious or highly suspicious for malignancy) were biopsied. There were 22 cancers detected (16 invasive and 6 ductal carcinoma in situ). Of these, 17 (77%) were detected by MRI vs 8 (36%) by mammography, 7 (33%) by ultrasound, and 2 (9.1%) by CBE. The sensitivity and specificity (based on biopsy rates) were 77% and 95.4% for MRI, 36% and 99.8% for mammography, 33% and 96% for ultrasound, and 9.1% and 99.3% for CBE, respectively. There was 1 interval cancer. All 4 screening modalities combined had a sensitivity of 95% vs 45% for mammography and CBE combined. CONCLUSIONS In BRCA1 and BRCA2 mutation carriers, MRI is more sensitive for detecting breast cancers than mammography, ultrasound, or CBE alone. Whether surveillance regimens that include MRI will reduce mortality from breast cancer in high-risk women requires further investigation.

[1]  D. Livingston,et al.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.

[2]  M D Schnall,et al.  MR imaging-guided localization and biopsy of breast lesions: initial experience. , 1994, Radiology.

[3]  J. Klijn,et al.  Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2 , 1997 .

[5]  D M Ikeda,et al.  Freehand iMRI‐guided large‐gauge core needle biopsy: A new minimally invasive technique for diagnosis of enhancing breast lesions , 2001, Journal of magnetic resonance imaging : JMRI.

[6]  L. Liberman,et al.  Breast lesions detected on MR imaging: features and positive predictive value. , 2002, AJR. American journal of roentgenology.

[7]  M D Schnall,et al.  Diagnostic performance characteristics of architectural features revealed by high spatial-resolution MR imaging of the breast. , 1997, AJR. American journal of roentgenology.

[8]  T. M. Kolb,et al.  Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. , 2002, Radiology.

[9]  P. Gordon.  Ultrasound for breast cancer screening and staging. , 2002, Radiologic clinics of North America.

[10]  P. Goss,et al.  Current perspectives on radiation-induced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R L Greenman,et al.  Bilateral imaging using separate interleaved 3D volumes and dynamically switched multiple receive coil arrays , 1998, Magnetic resonance in medicine.

[12]  D Krebs,et al.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. , 2000, Radiology.

[13]  J. Satagopan,et al.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M D Schnall,et al.  Correlation of lesion appearance and histologic findings for the nodes of a breast MR imaging interpretation model. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[16]  C A Kelsey,et al.  Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. , 1998, Radiology.

[17]  Donald B Plewes,et al.  Comparison of MR imaging breast coils. , 2002, Radiology.

[18]  C. Merritt,et al.  Toward a standardized breast ultrasound lexicon, BI-RADS: ultrasound. , 2001, Seminars in roentgenology.

[19]  A. Stavros,et al.  Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. , 1995, Radiology.

[20]  J O Barentsz,et al.  Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. , 2001, Journal of the National Cancer Institute.

[21]  S. Feig.  IARC Handbooks of Cancer Prevention , 2003 .

[22]  M D Schnall,et al.  Breast MR imaging: interpretation model. , 1997, Radiology.

[23]  D. Venter,et al.  The pathology of inherited breast cancer , 2002, Pathology.

[24]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[25]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[26]  G. Lenoir,et al.  In-situ breast cancer and BRCA 1 , 1996, The Lancet.

[27]  C. Boetes,et al.  MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC) , 2001, Familial Cancer.

[28]  C K Kuhl,et al.  MR imaging--guided large-core (14-gauge) needle biopsy of small lesions visible at breast MR imaging alone. , 2001, Radiology.

[29]  C. Kuhl,et al.  Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial , 2003 .

[30]  J. Lubiński,et al.  Re: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. , 2003, Journal of the National Cancer Institute.

[31]  Hybrid imaging guidance system for biopsy of the breast , 2001 .

[32]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[33]  M O Leach,et al.  The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). , 2002, Journal of experimental & clinical cancer research : CR.

[34]  E. Morris.  Illustrated breast MR lexicon. , 2001, Seminars in roentgenology.

[35]  B. Grube,et al.  MRI of occult breast carcinoma in a high-risk population , 2004 .

[36]  R. Warren,et al.  Screening women at high risk of breast cancer on the basis of evidence. , 2001, European journal of radiology.

[37]  Elizabeth A Morris,et al.  Fast MRI-guided vacuum-assisted breast biopsy: initial experience. , 2003, AJR. American journal of roentgenology.

[38]  Matthijs Oudkerk,et al.  First experiences in screening women at high risk for breast cancer with MR imaging , 2000, Breast Cancer Research and Treatment.

[39]  G. Newstead,et al.  MR imaging of the breast. , 1995, Radiology.

[40]  M. Berer.  Mammography in Asian patients with BRCA1 mutations , 1999, The Lancet.

[41]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[42]  R. Tollenaar,et al.  MRI screening for breast cancer in women with high familial and genetic risk: First results of the Dutch MRI screening study (MRISC). , 2003 .